Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A cell therapy involving the adoptive transfer of gamma-delta (γδ) T cells, developed by Shandong Province Qilu Stem Cells Engineering. γδ T cells are a unique subset of T cells that bridge innate and adaptive immunity, recognizing stress-induced ligands on infected or malignant cells in a Major Histocompatibility Complex (MHC)-independent manner. Upon recognition of these ligands, the γδ T cells mediate direct cytotoxicity through the release of perforin and granzymes and produce pro-inflammatory cytokines to orchestrate a broader immune response. This therapy is offered as part of the company's clinical research and service portfolio, targeting conditions where stress-induced ligands are expressed, such as various cancers and infectious diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gamma-delta T cell therapy (Shandong Province Qilu Stem Cells Engineering).